Inovio Pharmaceuticals Files 8-K with Material Agreement
Ticker: INO · Form: 8-K · Filed: Nov 12, 2025 · CIK: 1055726
| Field | Detail |
|---|---|
| Company | Inovio Pharmaceuticals, INC. (INO) |
| Form Type | 8-K |
| Filed Date | Nov 12, 2025 |
| Risk Level | medium |
| Pages | 4 |
| Reading Time | 4 min |
| Key Dollar Amounts | $0.001, $1.90, $26.5 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: material-agreement, filing
TL;DR
INOVIO just filed an 8-K for a material definitive agreement - big news incoming.
AI Summary
On November 11, 2025, Inovio Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also included other events and financial statements/exhibits. The company's principal executive offices are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462.
Why It Matters
This 8-K filing indicates Inovio Pharmaceuticals has entered into a significant new agreement, which could impact its business operations and future financial performance.
Risk Assessment
Risk Level: medium — Material definitive agreements can introduce new risks or opportunities that may affect the company's stock price.
Key Players & Entities
- INOVIO PHARMACEUTICALS, INC. (company) — Registrant
- November 11, 2025 (date) — Date of earliest event reported
- 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462 (location) — Business Address
- INOVIO BIOMEDICAL CORP (company) — Former Company Name
- GENETRONICS BIOMEDICAL CORP (company) — Former Company Name
FAQ
What is the nature of the material definitive agreement filed by Inovio Pharmaceuticals?
The filing indicates the entry into a material definitive agreement, but the specific details of the agreement are not provided in the provided text.
When was the earliest event reported in this 8-K filing?
The earliest event reported was on November 11, 2025.
What is Inovio Pharmaceuticals' primary business classification?
Inovio Pharmaceuticals, Inc. is classified under 'PHARMACEUTICAL PREPARATIONS [2834]'.
What are Inovio Pharmaceuticals' previous company names?
Inovio Pharmaceuticals, Inc. was formerly known as INOVIO BIOMEDICAL CORP and GENETRONICS BIOMEDICAL CORP.
Where are Inovio Pharmaceuticals' principal executive offices located?
Their principal executive offices are located at 660 W. Germantown Pike, Suite 110, Plymouth Meeting, PA 19462.
Filing Stats: 1,109 words · 4 min read · ~4 pages · Grade level 12.2 · Accepted 2025-11-12 06:16:08
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value INO The Nasdaq Stock Mark
- $1.90 — Stock "), at a public offering price of $1.90 per Share (the " Offering "). The Com
- $26.5 m — Stock, are expected to be approximately $26.5 million, after deducting the underwriting
Filing Documents
- d80000d8k.htm (8-K) — 33KB
- d80000dex11.htm (EX-1.1) — 189KB
- d80000dex51.htm (EX-5.1) — 8KB
- d80000dex991.htm (EX-99.1) — 7KB
- d80000dex992.htm (EX-99.2) — 7KB
- g80000g1112052616007.jpg (GRAPHIC) — 2KB
- g80000g1112052915419.jpg (GRAPHIC) — 2KB
- g80000g1112053002467.jpg (GRAPHIC) — 4KB
- g80000g1112053016279.jpg (GRAPHIC) — 4KB
- 0001193125-25-275721.txt ( ) — 441KB
- ino-20251111.xsd (EX-101.SCH) — 3KB
- ino-20251111_lab.xml (EX-101.LAB) — 18KB
- ino-20251111_pre.xml (EX-101.PRE) — 11KB
- d80000d8k_htm.xml (XML) — 4KB
Forward-Looking Statements
Forward-Looking Statements This Current Report on Form 8-K contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "anticipates," "believes," "expects," "intends," "projects," "plans," and "future" or similar expressions are intended to identify forward-looking statements. Forward-looking statements include statements concerning the Offering, such as the expected net proceeds and anticipated closing date. Forward-looking statements are based on management's current expectations and are subject to various risks and uncertainties that could cause actual results to differ materially and adversely from those expressed or implied by such forward-looking statements. Accordingly, these forward-looking statements do not constitute guarantees of future performance, and you are cautioned not to place undue reliance on these forward-looking statements. Risks regarding the Company's business are described in detail in its SEC filings, including in the Company's Annual Report on Form 10-K for the year ended December 31, 2024 and the Company's Quarterly Report on Form 10-Q for the quarter ended September 30, 2025, which are available on the SEC's website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. These forward-looking statements speak only as of the date hereof, and the Company disclaims any obligation to update these statements except as may be required by law. Item9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 1.1 Underwriting Agreement, dated November 11, 2025, by and between Inovio Pharmaceuticals, Inc. and Piper Sandler & Co. 5.1 Opinion of Cooley LLP. 23.1 Consent of Cooley LLP (included in Exhibit 5.1). 99.1 Press Release. 99.2 Press Release. 104 Cover Page Interactive Data File (formatted as inline XBRL).
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. INOVIO PHARMACEUTICALS, INC. Date: November 12, 2025 /s/ Peter Kies Peter Kies Chief Financial Officer